Pliant Therapeutics (PLRX) Competitors $1.55 -0.03 (-1.59%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.52 -0.03 (-1.94%) As of 08/15/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. GOSS, ERAS, RGNX, AQST, YMAB, HUMA, VIGL, EOLS, CYRX, and MBXShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Gossamer Bio (GOSS), Erasca (ERAS), REGENXBIO (RGNX), Aquestive Therapeutics (AQST), Y-mAbs Therapeutics (YMAB), Humacyte (HUMA), Vigil Neuroscience (VIGL), Evolus (EOLS), CryoPort (CYRX), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Gossamer Bio Erasca REGENXBIO Aquestive Therapeutics Y-mAbs Therapeutics Humacyte Vigil Neuroscience Evolus CryoPort MBX Biosciences Pliant Therapeutics (NASDAQ:PLRX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability. Do insiders & institutionals believe in PLRX or GOSS? 97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by insiders. Comparatively, 6.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, PLRX or GOSS? Pliant Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Do analysts rate PLRX or GOSS? Pliant Therapeutics presently has a consensus target price of $8.19, indicating a potential upside of 428.23%. Gossamer Bio has a consensus target price of $8.50, indicating a potential upside of 333.67%. Given Pliant Therapeutics' higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.08Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PLRX or GOSS more profitable? Pliant Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Pliant Therapeutics' return on equity of -73.45% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -73.45% -55.66% Gossamer Bio -344.81%-1,774.72%-46.73% Does the media refer more to PLRX or GOSS? In the previous week, Gossamer Bio had 13 more articles in the media than Pliant Therapeutics. MarketBeat recorded 19 mentions for Gossamer Bio and 6 mentions for Pliant Therapeutics. Gossamer Bio's average media sentiment score of 0.60 beat Pliant Therapeutics' score of 0.17 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, PLRX or GOSS? Gossamer Bio has higher revenue and earnings than Pliant Therapeutics. Gossamer Bio is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M60.22-$210.30M-$3.40-0.46Gossamer Bio$114.70M3.89-$56.53M-$0.62-3.16 SummaryGossamer Bio beats Pliant Therapeutics on 9 of the 16 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.69M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-0.4620.3830.5825.12Price / Sales60.22368.96464.24116.42Price / CashN/A42.3037.4059.05Price / Book0.438.659.096.18Net Income-$210.30M-$54.65M$3.25B$264.89M7 Day Performance-6.63%6.58%7.42%4.22%1 Month Performance15.67%7.54%5.50%2.02%1 Year Performance-87.65%13.73%30.67%24.22% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics3.8938 of 5 stars$1.55-1.6%$8.19+428.2%-87.5%$96.69M$1.58M-0.4690GOSSGossamer Bio3.8043 of 5 stars$1.73-1.5%$8.50+390.5%+137.7%$400.19M$114.70M-2.80180ERASErasca2.4289 of 5 stars$1.48+5.7%$4.57+208.9%-39.5%$396.60MN/A-2.39120News CoverageEarnings ReportRGNXREGENXBIO4.3224 of 5 stars$7.46-5.0%$28.38+280.4%-28.9%$396.54M$83.33M-2.17370AQSTAquestive Therapeutics2.0945 of 5 stars$3.86-1.0%$10.14+162.8%-0.2%$387.38M$57.56M-6.54160Trending NewsEarnings ReportAnalyst RevisionYMABY-mAbs Therapeutics2.7632 of 5 stars$8.52+0.1%$11.16+31.0%-30.2%$385.36M$87.68M-17.04150Earnings ReportHUMAHumacyte1.9849 of 5 stars$1.75-29.4%$11.71+569.4%-69.4%$384.70M$1.57M-2.54150Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeVIGLVigil Neuroscience3.4499 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340EOLSEvolus3.8989 of 5 stars$5.77-2.2%$21.25+268.3%-50.5%$381.64M$266.27M-5.89170CYRXCryoPort3.822 of 5 stars$8.09+7.0%$12.00+48.3%-4.1%$379.04M$228.38M6.081,186MBXMBX Biosciences2.5781 of 5 stars$11.26-7.4%$37.63+234.1%N/A$376.35MN/A-2.4836News CoverageAnalyst Forecast Related Companies and Tools Related Companies GOSS Alternatives ERAS Alternatives RGNX Alternatives AQST Alternatives YMAB Alternatives HUMA Alternatives VIGL Alternatives EOLS Alternatives CYRX Alternatives MBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access